AGENUS INC Debt Conversion, Converted Instrument, Amount
AGENUS INC (AGEN) reported Debt Conversion, Converted Instrument, Amount of $0 for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2017-03-16
- AGENUS INC debt conversion, converted instrument, amount for the quarter ending 2014-12-31 was $0.00.
- AGENUS INC debt conversion, converted instrument, amount for fiscal 2014 was $953.76K, a 91.54% decline from fiscal 2013.
- AGENUS INC debt conversion, converted instrument, amount for fiscal 2013 was $11.28M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|
| 2015-09-30 | $0.00 10-Q · filed 2015-11-04 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $953.76K 10-K · filed 2017-03-16 | |
| 2014-09-30 | $953.76K 10-Q · filed 2015-11-04 | ||
| 2013-12-31 | $11.28M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |